Introduction
In 1992, Gagner and Pomp reported the world's first case of laparoscopic pancreaticoduodenectomy (LPD) [
1]. Nowadays LPD is now approved as safe and feasible in high-volume centers and may be associated with a shorter time to functional recovery and shorter hospital stay than open pancreaticoduodenectomy (OPD) [
2,
3]. However, combining a challenging resection and multiple anastomoses remains a technical difficulty. Single-incision laparoscopic surgery (SILS) has been widely used in gynecological and thoracic surgery with many benefits, including a reduced risk of trocar-related complications, reduced postoperative pain, and improved convalescence and cosmetic results [
4,
5]. However, only a few single-incision LPD (SILPD) cases have been described [
6]. From February 2020 to December 2020, we finished 13 SILPDs and found them feasible with several potential advantages mentioned above [
7]. However, SILPD is much more challenging owing to a limited range of motion, instrument crowding, and collision, difficulty in bleeding control, and longer operative time [
7]. Single-incision plus one-port surgery has been reported in distal pancreatectomy and rectosigmoid cancer as possibly safer and more feasible without losing those benefits compare with SILS [
8,
9]. However, the safety, efficacy, and advantages of single-incision plus one-port LPD (SILPD + 1) have never been reported. In this article, we decided to evaluate the short-term outcomes of SILPD + 1 compared with those of conventional LPD (CLPD).
Results
The demographic characteristics and perioperative outcomes of patients who underwent SILPD + 1 are shown in Table
1. The patient population included three male and seven female patients with a mean age of 47.2 (range = 18.0–73.0) years and a median BMI of 21.0 (range = 19.8–27.1) kg/m
2. The postoperative pathologic diagnosis included five cases of pancreatic ductal adenocarcinoma and one case each of duodenal papilla tumor, pancreatic neuroendocrine tumor, serous cystadenoma, pancreatic neuroendocrine tumor, and chronic pancreatitis. Two (20%) patients had portal-vein involvement with wedge resection. The median operative time was 222.5 (range 194.0–300.0) min. The median blood loss was 75.0 (range = 50–250) mL. One (10%) patient developed a pancreatic fistula (grade B). One (10%) patient had a major postoperative complication (Clavien–Dindo ≥ grade 3) requiring reoperation in laparoscope as afferent loop obstruction. However, no patient suffered postoperative bleeding, biliary leakage, and grade C pancreatic fistula. No 90-day mortality was found.
Table 1
Data of the patients who underwent single-incision plus one-port laparoscopic pancreaticoduodenectomy
1 | Female | 24 | 25.1 | VPC | 1.1 | 223 | No | 7 | 20 | 9 | None |
2 | Male | 65 | 27.1 | PDCA | 1.8 | 260 | No | 25 | 150 | 15 | Biochemical leakage |
3 | Male | 58 | 20.6 | CP | 2.0 | 220 | No | NN | 250 | 17 | Biochemical leakage |
4 | Male | 38 | 22.7 | PDCA | 2.2 | 300 | Yes | 22 | 200 | 38 | Pancreatic fistula (Grade B), Chylous leakage |
5 | Female | 55 | 20.4 | PDCA | 2.0 | 240 | Yes | 19 | 100 | 25 | Diarrhea |
6 | Female | 73 | 20.3 | PDCA | 4.0 | 205 | No | 18 | 50 | 10 | None |
7 | Female | 63 | 24.6 | TDP | 1.6 | 222 | No | NN | 30 | 10 | None |
8 | Female | 18 | 21.4 | PNET | 2.6 | 210 | No | 8 | 100 | 14 | Biochemical leakage, Reoperation (Laparoscope) |
9 | Female | 40 | 19.8 | PDCA | 4.0 | 230 | No | 20 | 26 | 8 | Biochemical leakage, diarrhea |
10 | Female | 38 | 20.0 | SCA | 5.2 | 194 | No | NN | 20 | 14 | None |
The demographic characteristics of the two groups are compared in Table
2. The two groups did not statistically differ in sex, BMI, ASA score, laboratory examination, tumor size, pancreatic duct diameter, gland texture, and pathological diagnosis (all
P > 0.05). Patients were younger in the SILPD + 1 group (47.2 ± 18.3 years vs. 60.6 ± 11.7 years,
P = 0.05) than that in the CLPD group.
Table 2
The demographic characteristics of two groups
Age, mean (SD), y | 47.2 (18.3) | 60.6 (11.7) | 0.050 |
Sex, (male/female), n | 3/7 | 29/18 | 0.913 |
BMI, mean (SD), kg/m2 | 21.0 (2.6) | 22.8 (3.6) | 0.567 |
ASA score | _ | _ | 1.000 |
II, n (%) | 9 (90) | 41 (87.2) | _ |
III, n (%) | 1 (10) | 6 (12.8) | _ |
History of abdominal surgerya, n (%) | 1 (10.0) | 8(17) | 0.940 |
Preoperative biliary drainage, n (%) | 1 (10.0) | 7(14.9) | 1.000 |
Hemoglobin, mean (SD), g/L | 127.8 (15.4) | 128.6 (24.8) | 0.927 |
Albumin, mean (SD), g/L | 39.7 (2.9) | 40.3 (5.2) | 0.627 |
TB, median (IQR), μmol/L | 11.8 (8.0–43.8) | 15.7 (10.5–86.0) | 0.285 |
Tumor size, mean (SD), cm | 2.7 (1.3) | 2.5 (1.2) | 0.711 |
Diameter of Pancreatic duct, median (IQR), mm | 5 (2.8–6.3) | 3 (2.5–5.0) | 0.311 |
Gland texture (Firm/Soft), n | 5/5 | 18/29 | 0.741 |
Diagnosis | | | 0.819 |
Duodenum cancer, n (%) | 0 (0) | 4 (8.5) | _ |
PDAC, n (%) | 5 (50.0) | 17 (36.2) | _ |
CCBD, n (%) | 0 (0) | 3 (6.4) | _ |
CP, n (%) | 1 (10.0) | 2 (4.3) | _ |
PNET, n (%) | 1 (10.0) | 4 (8.5) | |
Pancreatic cystic tumorsb, n (%) | 1 (10.0) | 5 (10.6) | _ |
TDP, n (%) | 1(10.0) | 6 (12.8) | |
Othersc, n (%) | 1 (0) | 6 (12.8) | |
The surgical and postoperative outcomes of these patients are shown in Table
3. None of the patients needed additional port insertion or conversion to laparotomy. Median operation time (222.5 (208.8–245.0) vs. 305.0 (256.0–337.0) min,
P < 0.001) was shorter in SILPD + 1 than in CLPD. The estimated blood loss, blood-transfusion rate, exhaust time, time of drainage tube removal, and postoperative hospital stay were comparable between the two groups. Median postoperative VAS in day 1 (2.5 (2.0–3.0) vs. 3.0 (3.0–4.0),
P < 0.001), day 2 (2.0 (1.75–2.0) vs. 2.0 (2.0–3.0)),
P = 0.039) and day 3 (1.5 (1.0–2.0) vs. 2.0 (1.0–3.0),
P = 0.001) were lower in SILPD + 1 group than in CLPD. The median cosmetic score (21.0 (19.0–23.5) vs. 17.0 (16.0–20.0),
P = 0.026) was higher in SILPD + 1 than in CLPD one month after the surgery. The overall complications were comparable between the two groups. The patients in SILPD + 1 developed fewer grade B and C pancreatic fistulas (10.0% vs. 19.1%,
P = 0.816), had lesser DGE (10 vs. 12.8%,
P = 1.00), and fewer PPH (0 vs. 10.6%,
P = 0.574) than those in the CLPD group. However, the difference was not significant.
Table 3
Intraoperative and postoperative outcomes of two groups
Operative time, median (IQR), min | 222.5 (208.8–245.0) | 305.0(256.0–337.0) | < 0.001 |
Venous resection, n (%) | 2 (20.0) | 0 (0) | 0.028 |
Conversion, n (%) | 0 (0) | 0 (0) | 1.000 |
Transfusion, n (%) | 0 (0) | 5 (10.6) | 0.574 |
EBL, median (IQR), mL | 75.0 (24.5–162.5) | 100.0 (50.0–200.0) | 0.101 |
POHS, median (IQR), d | 14.0 (9.8–19.0) | 14.0 (10.0–23.0) | 0.562 |
Exhaust time, median (IQR), d | 2.0 (2.0–3.0) | 3.0 (2.0–4.0) | 0.088 |
Time of drainage tube remove, median (IQR), d | 9.0 (6.0–12.3) | 9.0 (6.0–13.0) | 0.975 |
Postoperative VAS, median (IQR), p |
Day1 | 2.5 (2.0–3.0) | 3.0 (3.0–4.0) | < 0.001 |
Day 2 | 2.0 (1.75–2.0) | 2.0 (2.0–3.0) | 0.039 |
Day 3 | 1.5 (1.0–2.0) | 2.0 (1.0–3.0) | 0.001 |
Biochemical leakage, n, (%) | 4 (40) | 14 (29.8) | 0.798 |
CR-POPFa, n (%) | 1 (10.0) | 9 (19.1) | 0.816 |
Hemorrhage, n (%) | 0 (0) | 5 (10.6) | 0.574 |
DGE, n (%) | 1 (10.0) | 6 (12.8) | 1.000 |
Reoperation, n (%) | 1 (10.0) | 2 (4.3) | 0.446 |
Chylous leakage, n (%) | 1 (10.0) | 2 (4.3) | 0.446 |
Biliary fistula, n (%) | 0 (0) | 3 (6.4) | 1.000 |
Abdominal infection, n (%) | 0 (0) | 1 (2.1) | 1.000 |
Incision infection, n (%) | 0 (0) | 3 (6.4) | 1.000 |
Clavien–Dindo classification | _ | _ | 0.281 |
I-II, n (%) | 6 (60.0) | 17 (36.2) | _ |
≥ III, n (%) | 1 (10.0) | 3 (6.4) | _ |
90-Day Mortality, n (%) | 0 (0) | 1 (2.1) | 1.000 |
Cosmetic scoreb, median (IQR), p | 21.0 (19.0–23.5) | 17.0 (16.0–20.0) | 0.026 |
Discussion
SILS is an important branch of laparoscopic technology that has been performed in almost every field of surgery, such as general surgery, gynecology, urology, and thoracic [
4,
5]. SILS offers potential benefits over conventional laparoscopic surgery, including a reduced risk of trocar-related complications, reduced postoperative pain, and improved convalescence and cosmetic results [
17‐
19]. LPD is a more technical challenge, and the first research on SILPD was reported [
6] in 2022. The main reason for the slow development of SILPD may be the technical challenges, conflicts of surgical devices, and the lack of triangulation and inline viewing [
17‐
19].
Between March 2013 and December 2019, three pancreatic ductal adenocarcinoma patients were reported with longer operative time (481.7 min) and higher blood loss (800 mL) [
6]. For highly selected patients, we began performing SILPD in May 2020 and finished 13 SILPDs. The median operative time was 340 (310–356) min, and the median EBL was 50 (50–125) mL (data not shown in this paper). We also found some other benefits like low pneumoperitoneal pressure and reducing the participation of assistants [
7]. Compared with our 550 CLPDs in a previous study, SILPD had longer median operation time (340 (310–356) vs. 323.5 (250 –420) min) but lower median EBL (50 (50–125) vs. 200 (120–300) mL) [
2]. We used only one scope port and two operation ports in SILPD, so the number of instruments was limited and patients should be highly selected [
7]. In particular, the assistant cannot use the suction device to remove the blood and surgical smoke from time to time, which impaired the clarity of vision and required very careful dissociation to avoid bleeding in SILPD. Herein, the retraction devices made with bulldog forceps were extremely important [
7]. We clamped the organs using the bulldog forceps and pulled the thread at the end of the forceps out of the abdominal wall to assist in time-consuming exposure. To decrease these difficulties, we have added one operating port for device manipulation, which no one had reported before. Through this port, the abovementioned technical challenges can be better resolved while preserving the minimally invasive benefits of SILPD. We can also use this port for drainage, which is very hard in SILPD. Thus, SILS + 1 surgery provides a more feasible option for LPD.
We also found the that operation time (222.5 (208.8–245.0) min) of SILPD + 1 decreased significantly, and it was even faster than that of the CLPD group (305.0 (256.0–337.0) min in this research and (323.5 (250–420) min) in a previous study) [
2]. The main reasons were including highly selected patients and fewer assistant participants in SILDP + 1, which can reduce the influence of the assistants’ experience on operation time in CLPD. It was similar to the result in laparoscopic distal gastrectomy, and this difference was also attributed to using extracorporeal gastrojejunostomy for SILPD + 1 and intracorporeal gastrojejunostomy for CLPD [
20]. However, SILPD + 1 resulted in a certain decrease in interference between instruments and scope compared with SILPD. We even finished two LPDs combined with vascular resection and reconstruction in SILPD + 1. No statistically significant differences were observed in postoperative complications. SILPD + 1 further showed lower postoperative pain and higher cosmetic results than the CLPD group. This finding was consistent with that of Liu [
21] for rectosigmoid cancer. Therefore, the safety and effectiveness of this surgical method are supported.
Reduced‐port robotic pancreaticoduodenectomy has been reported by Cho‐Han Chiang [
22]. They found that reduced-port RPD is associated with less blood loss but a longer operative time than OPD. Meanwhile, no studies have compared reduced‐port a robot to perform pancreaticoduodenectomy and SILPD or SILPD + 1. In theory, using a robotic to do single-port surgery has more advantages such as fewer assistants and less instrument interference. The limitations of the single-port surgical robot system included not being as popular as laparoscopy and the high cost in our country. Very few hospitals have this system.
The major limitation of this study was its retrospective nature with small sample size. As such, the treatment strategy was not based on random assignment, and the patients were highly selected. Another limitation was that data were obtained from a center with a high volume of patients, which may have influenced the results. Accordingly, we suggest conducting a multicenter prospective randomized controlled study in the future.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.